FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The increasing prevalence of STDs is one of the key factors expected to trigger the market’s growth in the forthcoming years. STDs are rising in the emerging and advanced economies, resulting in the rising demand for drugs and therapies for treating these chronic illnesses. The cases of these incidences has increased considerably in the recent years owing to the transmission of different bacteria, viruses, and parasites during sexual contact. As a result, the increasing prevalence of STDs will further propel the demand for drugs and therapies, in turn, contributing significantly to the STD treatment market growth during the forecast period. The analysts have predicted that the sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Viral infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Viral infections - Year-over-year growth 2019-2023 (%)
Exhibit 21: Bacterial infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Bacterial infections - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other infections - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Pipeline drugs for STDs
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Some of the HIV vaccines under clinical trials
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bristol-Myers Squibb Company - Vendor overview
Exhibit 48: Bristol-Myers Squibb Company - Business segments
Exhibit 49: Bristol-Myers Squibb Company - Organizational developments
Exhibit 50: Bristol-Myers Squibb Company - Geographic focus
Exhibit 51: Bristol-Myers Squibb Company - Key offerings
Exhibit 52: Gilead Sciences, Inc. - Vendor overview
Exhibit 53: Gilead Sciences, Inc. - Business segments
Exhibit 54: Gilead Sciences, Inc. - Organizational developments
Exhibit 55: Gilead Sciences, Inc. - Geographic focus
Exhibit 56: Gilead Sciences, Inc. - Key offerings
Exhibit 57: GlaxoSmithKline plc - Vendor overview
Exhibit 58: GlaxoSmithKline plc - Business segments
Exhibit 59: GlaxoSmithKline plc - Organizational developments
Exhibit 60: GlaxoSmithKline plc - Geographic focus
Exhibit 61: GlaxoSmithKline plc - Segment focus
Exhibit 62: GlaxoSmithKline plc - Key offerings
Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 69: Merck & Co., Inc. - Vendor overview
Exhibit 70: Merck & Co., Inc. - Business segments
Exhibit 71: Merck & Co., Inc. - Organizational developments
Exhibit 72: Merck & Co., Inc. - Geographic focus
Exhibit 73: Merck & Co., Inc. - Segment focus
Exhibit 74: Merck & Co., Inc. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Viral infections - Market size and forecast 2018-2023
- Bacterial infections - Market size and forecast 2018-2023
- Other infections - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Research methodology
- List of abbreviations
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Viral infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Viral infections - Year-over-year growth 2019-2023 (%)
Exhibit 21: Bacterial infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Bacterial infections - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other infections - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Pipeline drugs for STDs
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Some of the HIV vaccines under clinical trials
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bristol-Myers Squibb Company - Vendor overview
Exhibit 48: Bristol-Myers Squibb Company - Business segments
Exhibit 49: Bristol-Myers Squibb Company - Organizational developments
Exhibit 50: Bristol-Myers Squibb Company - Geographic focus
Exhibit 51: Bristol-Myers Squibb Company - Key offerings
Exhibit 52: Gilead Sciences, Inc. - Vendor overview
Exhibit 53: Gilead Sciences, Inc. - Business segments
Exhibit 54: Gilead Sciences, Inc. - Organizational developments
Exhibit 55: Gilead Sciences, Inc. - Geographic focus
Exhibit 56: Gilead Sciences, Inc. - Key offerings
Exhibit 57: GlaxoSmithKline plc - Vendor overview
Exhibit 58: GlaxoSmithKline plc - Business segments
Exhibit 59: GlaxoSmithKline plc - Organizational developments
Exhibit 60: GlaxoSmithKline plc - Geographic focus
Exhibit 61: GlaxoSmithKline plc - Segment focus
Exhibit 62: GlaxoSmithKline plc - Key offerings
Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 69: Merck & Co., Inc. - Vendor overview
Exhibit 70: Merck & Co., Inc. - Business segments
Exhibit 71: Merck & Co., Inc. - Organizational developments
Exhibit 72: Merck & Co., Inc. - Geographic focus
Exhibit 73: Merck & Co., Inc. - Segment focus
Exhibit 74: Merck & Co., Inc. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
The analyst recognizes the following companies as the key players in the global sexually transmitted diseases (STD) treatment market: Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., and Merck & Co., Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in the rapid diagnosis of STDs.”
According to the report, one of the major drivers for this market is the initiatives to increase funding and awareness about STDs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of novel antiviral therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global sexually transmitted diseases (STD) treatment market: Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., and Merck & Co., Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in the rapid diagnosis of STDs.”
According to the report, one of the major drivers for this market is the initiatives to increase funding and awareness about STDs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of novel antiviral therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
Note: Product cover images may vary from those shown
LOADING...
